Drug transporters at brain barriers expression and regulation by neurological disorders

Advances in Experimental Medicine and Biology

Volumn 763, Issue , 2013, Pages 20-69

  Ashraf, Tamima ^a   Kis, Olena ^a   Banerjee, Nilasha ^a   Bendayan, Reina ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATASE; ATAZANAVIR; BREAST CANCER RESISTANCE PROTEIN; COLCHICINE; DRUG TRANSPORTER; ELVITEGRAVIR; GLYCOPROTEIN P INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUKOTRIENE C4; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; NUCLEOSIDE; NUCLEOTIDE BINDING PROTEIN; ORGANIC ANION TRANSPORTER; PEPTIDE TRANSPORTER 1; PEPTIDE TRANSPORTER 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLCHOLINE; PROGESTERONE; PROTEIN KINASE C; RITONAVIR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABCB1 GENE; ABCG2 GENE; ACTIVE TRANSPORT; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN CANCER; BRAIN CAPILLARY ENDOTHELIAL CELL; CAPILLARY FLOW; CELL FUNCTION; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CEREBROSPINAL FLUID; CHOROID PLEXUS; COCULTURE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIMERIZATION; ELECTRON MICROSCOPY; ENDOCYTOSIS; ENVIRONMENTAL FACTOR; ENZYME SPECIFICITY; EPILEPSY; GENE; HUMAN; HYDROLYSIS; IMMUNOSURVEILLANCE; INTERSTITIAL FLUID; LIPID BILAYER; LIPOPHILICITY; MICRODIALYSIS; MICROGLIA; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; OLIGODENDROGLIA; PARKINSON DISEASE; PERICYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MICROARRAY; PROTEIN MOTIF; PROTEIN TRANSPORT; RADIATION NECROSIS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SYSTEMIC CIRCULATION; TRANSCYTOSIS; UPREGULATION; VIRUS ENCEPHALITIS;

EID: 84934441079     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-4711-5_2     Document Type: Article

References (303)

1. Abbott NJ. Patabcndigc AA, Dolman DE, et al. Structurc and function ofthc blood-brain barricr. Ncurobiol Dis 2010; 37: 13-25
2. Rccsc TS, Kamovsky MJ. Finc structural localization of a blood-brain barricr to cxogcnous pcroxidasc. JCell BioI 1967; 34:207-217
3. Fishcr M. Pcricytc signaling in thc ncurovascular unit. Strokc 2009; 40:S 13-S 15
4. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Ncurosci 2006; 7:41-53
5. Neuwelt EA, Bauer B, Fahlke C, et al. Engaging neuroscience to advance translational research in brain barricr biology. Nat Rcv Ncurosci 2011; 12:169-182
6. Wu DT, Woodman SE, Weiss JM, et al. Mechanisms of leukocyte trafficking into the CNS. J Neurovirol 2000; 6 Suppll :S82-S85
7. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57:173-185
8. McCarthy KM, Skare lB, Stankewich MC, et al. Occludin is a functional component of the tight junction. J Cell Sci 1996; 109:2287-2298
9. Pardridge WM. Transport of insulin-related peptides and glucose across the blood-brain barrier. Ann N Y Acad Sci 1993; 692:126-137
10. Persidsky Y, Ramirez SH, Haorah J, et al. Blood-brain barrier: Structural components and function under physiologic and pathologic conditions. J Ncuroimmunc Pharmacol2006; 1:223-236
11. De Vries HE, Kuiper J, De Boer AG, et al. The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rcv 1997; 49:143-155
12. Volterra A, Meldolesi J. Astrocytes, from brain glue to communication elements: The revolution continues. Nat Rcv Ncurosci 2005; 6:626-640
13. Janzer RC, Raff MC. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 1987; 325:253-257
14. Anderson CM, Swanson RA. Astrocyte glutamate transport: Reviewofproperties, regulation, and physiological functions. Glia 2000; 32:1-14
15. Benarroch EE. Neuron-Astrocyte interactions: Partnership for normal function and disease in the central ncrvous systcm. Mayo Clin Proc 2005; 80: 1326-1338
16. Pardridge WM, Golden PL, Kang YS, et al. Brain microvascular and astrocyte localization ofP-glycoprotein. J Ncurochcm 1997; 68:1278-1285
17. Hirrlinger J, Moeller H, KirchhoffF, et al. Expression of multidrug resistance proteins (Mrps) in astrocytes ofthc mousc brain: A single cell RT-PCR study. Ncurochcm Rcs 2005; 30:1237-1244
18. Mrak RE, Griffin WS. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 2005; 26:349-354
19. Gorry PR, Ong C, Thorpe J, et al. Astrocyte infection by HIV-I: Mechanisms of restricted virus replication, and rolc in thc pathogcncsis of HIV-I-Associatcd dcmcntia. Curr HIV Rcs 2003; 1:463-473
20. Sidoryk-Wegrzynowicz M, Wegrzynowicz M, Lee E, et al. Role of astrocytes in brain function and disease. Toxicol Pathol20 11; 39: 115-123
21. Hori S, Ohtsuki S, Hosoya K, et al. A pericyte-derived angiopoietin-I multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie-2 activation in vitro. J Neurochem 2004; 89:503-513
22. Dore-Duffy P. Pericytes: Pluripotent cells ofthe blood brain barrier. Curr Pharm Des 2008; 14: 1581-1593
23. Berezowski Y, Landry C, Dehouck MP, et al. Contribution of glial cells and pericytes to the mRNA profiles of P-glycoprotein and multidrug resistance-Associated proteins in an in vitro model of the blood-brain barrier. Brain Res 2004; 20(1018): 1-9.
24. Kobayashi H, Magnoni MS, Govoni S, et al. Neuronal control of brain microvessel function. Experientia 1985; 41:427-434
25. Vaucher E, Tong XK, Cholet N, et al. GABA neurons provide a rich input to microvessels but not nitric oxide neurons in the rat cerebral cortex: A means for direct regulation of local cerebral blood flow. J Comp Neuro12000; 421:161-171
26. Tarawneh R, Galvin JE. Potential future neuroprotective therapies for neurodegenerative disorders and stroke. Clin Geriatr Med 2010; 26: 125-147
27. Busch AE, Karbach U, Miska D, et al. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 1998; 54:342-352
28. Garden GA, Moller T. Microglia biology in health and disease. J Neuroimmune Pharmacol2006; 1: 127-137
29. Lee G, Schlichter L, Bendayan M, et al. Functional expression of P-glycoprotein in rat brain microglia. J Pharmacol Exp Ther 2001; 299:204-212
30. Hirrlinger J, Konig J, Dringen R. Expression ofmRNAs of multi drug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurones. J Neurochem 2002; 82:716-719
31. Lee G, Dallas S, Hong M, et al. Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations. Pharmacol Rev 2001; 53:569-596
32. Dallas S, Zhu X, Baruchel S, et al. Functional expression of the multidrug resistance protein I in microglia. J Pharmacol Exp Ther 2003; 307:282-290
33. Dallas S, Miller DS, Bendayan R. Multidrug resistance-Associated proteins: Expression and function in the central nervous system. Pharmacol Rev 2006; 58:140-161
34. Dallas S, Schlichter L, Bendayan R. Multidrug resistance protein (MRP) 4-And MRP 5-mediated efflux of9-(2-phosphonylmethoxyethyl) adenine by microglia. J Pharmacol Exp Ther 2004; 309:1221-1229
35. Ronaldson PT, Persidsky Y, Bendayan R. Regulation of ABC membrane transporters in glial cells: Relevance to the pharmacotherapy of brain HIV-1 infection. Glia 2008; 56: 1711-1735
36. Ronaldson PT, Bendayan M, Gingras D, et al. Cellular localization and functional expression ofP-glycoprotein in rat astrocyte cultures. J Neurochem 2004; 89:788-800
37. Benarroch EE. Oligodendrocytes: Susceptibility to injury and involvement in neurologic disease. Neurology 2009; 19(72): 1779-1785
38. Spector R, Johanson CE The mammalian choroid plexus. Sci Am 1989; 261 :68-74
39. Segal MB. The choroid plexuses and the barriers between the blood and the cerebrospinal fluid. Cell Mol Neurobiol2000; 20:183-196
40. Davson H, Hollingsworth G, Segal MB. The mechanism of drainage of the cerebrospinal fluid. Brain 1970; 93:665-678
41. De Lange EC. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv Drug Deliv Rev 2004; 56: 1793-1809
42. Kusuhara H, Sugiyama Y. Efflux transport systems for organic anions and cations at the blood-CSF barrier. Adv Drug Deliv Rev 2004; 56: 1741-1763
43. Cohen BE, Bangham AD. Diffusion of small non-electrolytes across liposome membranes. Nature 1972; 236: 173-174
44. Camenisch G, Alsenz J, van De WH, et al. Estimation of permeability by passive diffusion through Caco-2 cell mono layers using the drugs' lipophilicity and molecular weight. Eur J Pharm Sci 1998; 6:317-324
45. Van De WH, Camenisch G, Folkers G, et al. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 1998; 6: 151-165
46. Sugano K, Kansy M, Artursson P, et al. Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov 2010; 9:597-614
47. Gerencser GA, Stevens BR. Thermodynamics of symport and antiport catalyzed by eloned or native transporters. J Exp Bioi 1994; 196:59-75
48. Crone C. Facilitated transfer of glucose from blood into brain tissue. J Physiol 1965; 181: 103-113
49. Nelson N. Energizing porters by proton-motive force. J Exp Bioi 1994; 196:7-13
50. Simionescu M, Gafencu A, Antohe F. Transcytosis of plasma macromolecules in endothelial cells: A cell biological survey. Microsc Res Tech 2002; 57:269-288
51. Ghinea N, Hasu M. Charge effect on binding, uptake and transportofferritin through fenestrated endothelium. J Submierose Cyto11986; 18:647-659
52. Voinea M, Dragomir E, Manduteanu I, et al. Binding and uptake of transferrin-bound liposomes targeted to transferrin receptors of endothelial cells. Vaseul Pharmaeol2002; 39: 13-20
53. OldendorfWH. Measurement of brain uptake ofradiolabeled substances using a tritiated water internal standard. Brain Res 1970; 24:372-376
54. Van Bree JB, De Boer AG, DanhofM, et al. Drug transport across the blood-brain barrier. III. Mechanisms and methods to improve drug delivery to the central nervous system. Pharm World Sci 1993; 19( 15):2-9
55. Parsons LH, Justice JB Jr. Quantitative approaches to in vivo brain mierodialysis. Crit Rev Neurobiol 1994; 8: 189-220
56. Shen DD, Artru AA, Adkison KK. Principles and applicability ofCSF sampling for the assessment ofCNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 2004; 56: 1825-1857
57. Cisternino S, Rousselle C, Debray M, et al. In situ transport of vinblastine and selected P-glyeoprotein substrates: Implications for drug-drug interactions at the mouse blood-brain barrier. Pharm Res 2004; 21: 1382-1389
58. Takasato Y, Rapoport SI, Smith QR. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol 1984; 247:H484-H493
59. Mensch J, Oyarzabal J, Mackie C, et al. In vivo, in vitro and in silieo methods for small molecule transfer across the BBB. J Pharm Sci 2009; 98:4429-4468
60. Bendayan R, Lee G, Bendayan M. Functional expression and localization of P-glyeoprotein at the blood brain barrier. Mierose Res Tech 2002; 57:365-380
61. Ronaldson PT, Lee G, Dallas S, et al. Involvement of P-glyeoprotein in the transport of saquinavir and indinavir in rat brain mierovessel endothelial and microglia cell lines. Pharm Res 2004; 21 :811-818
62. Deli MA, Abraham CS, Kataoka Y, et al. Permeability studies on in vitro blood-brain barrier models: Physiology, pathology, and pharmacology. Cell Mol Neurobiol2005; 25:59-127
63. Poller B, Gutmann H, Krahenbuhl S, et al. The human brain endothelial cell line hCMECID3 as a human blood-brain barrier model for drug transport studies. J Neuroehem 2008; 107: 1358-1368
64. Dauehy S, Miller F, Couraud PO, et al. Expression and transcriptional regulation of ABC transporters and eytoehromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Bioehem Pharmaeol 2009; 77:897-909
65. Meyer J, Rauh J, Galla HJ The susceptibility of cerebral endothelial cells to astroglial induction ofblood-brain barrier enzymes depends on their proliferative state. J Neuroehem 1991; 57:1971-1977
66. Hong M, Schlichter L, Bendayan R. A Na( + )-dependent nucleoside transporter in microglia. J Pharmaeol Exp Ther 2000; 292:366-374
67. Schlichter LC, Sakellaropoulos G, Ballyk B, et al. Properties ofK+ and CI-channels and their involvement in proliferation of rat microglial cells. Glia 1996; 17:225-236
68. Hong M, Schlichter L, Bendayan R. A novel zidovudine uptake system in microglia. J Pharmaeol Exp Ther 2001; 296:141-149
69. Dean M, Allikmets R. Complete characterization of the human ABC gene family. J Bioenerg Biomembr 2001; 33:475-479
70. Zhou SF. Structure, function and regulation ofP-glyeoprotein and its clinical relevance in drug disposition. Xenobiotiea 2008;38:802-32
71. Deeley RG and Cole SP. Substrate recognition and transport by multi drug resistance protein I (ABCCI FEBS Lett 2006; 580: 1103-11
72. Kim RB. Drugs as P-glyeoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002;34:47-54
73. Loseher W, Potsehka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosei 2005; 6:591-602
74. Sharom F J. ABC multi drug transporters: Structure, function and role in chemoresistance. Pharmaeogenomies 2008; 9:105-127
75. Hollenstein K, Dawson RJ, Locher KP. Structure and mechanism of ABC transporter proteins. Curr Opin Struet Bioi 2007; 17:412-418
76. Borst P, van Blitterswijk WJ, Borst J, et al. New physiological functions for drug-Transporting P-glyeoproteins? Drug Resist Updat 1998; 1:337-339
77. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliv Rev 2003; 55:3-29
78. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Bioehim Biophys Acta 1976; 455: 152-162
79. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdrl (P-glyeoprotein) gene from multidrug-resistant human cells. Cell 1986; 47:381-389
80. Gottesman MM, Hryeyna CA, Sehoenlein PV, et al. Genetic analysis of the multidrug transporter. Annu Rev Genet 1995; 29:607-649
81. Loo TW, Clarke DM. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Bioi 2005; 206:173-185
82. Rosenberg MF, Kamis AB, Callaghan R, et al. Three-dimensional structures of the mammalian multi drug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J BioI Chern 2003; 278:8294-8299
83. Aller SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009; 323: 1718-1722
84. Demeule M, Regina A, Jodoin J, et al. Drug transport to the brain: Key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol2002; 38:339-348
85. Lee G, Dallas S, Hong M, et al. Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations. Pharmacol Rev 2001; 53:569-596
86. Edwards JE, Alcorn J, Savolainen J, et al. Role of P-glycoprotein in distribution of nelfinavir across the blood-mammary tissue barrier and blood-brain barrier. Antimicrob Agents Chemother2005; 49: 1626-1628
87. Su L, Cheng CY, Mruk DD. Drug transporter, P-glycoprotein (MDRI), is an integrated component of the mammalian blood-Testis barrier. Tnt J Biochem Cell Bioi 2009; 41 :2578-2587
88. Bendayan R, Ronaldson PT, Gingras D, et al. In situ localization of P-glycoprotein (ABCB I) in human and rat brain. J Histochem Cytochem 2006; 54: 1159-1167
89. Virgintino D, Robertson D, Errede M, et al. Expression of P-glycoprotein in human cerebral cortex microvessels. J Histochem Cytochem 2002; 50: 1671-1676
90. Beaulieu E, Demeule M, Ghitescu L, et al. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 1997; 326:539-544
91. Miller DS, Nobmann SN, Gutmann H, et al. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol Pharmacol2000; 58:1357-1367
92. Lee G, Bendayan R. Functional expression and localization ofP-glycoprotein in the central nervous system: Relevance to the pathogenesis and treatment of neurological disorders. Pharm Res 2004; 21: 1313-1330
93. Rao VV, Dahlheimer JL, Bardgett ME, et al. Choroid plexus epithelial expression ofMDRI P-glycoprotein and multidrug resistance-Associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 1999; 96:3900-3905
94. Washington CB, Wiltshire HR, Man M, et al. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab Dispos 2000; 28: I 058-1062
95. Shaik N, Giri N, Pan G, et al. P-glycoprotein-mediated active efflux of the anti-HTVI nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos 2007; 35:2076-2085
96. Ronaldson PT, Bendayan R. HTV-I viral envelope glycoprotein gpl20 triggers an inflammatory response in cultured rat astrocytes and regulates the functional expression of P-glycoprotein. Mol Pharmacol 2006; 70: I 087-1 098
97. Lee G, Piquette-Miller M. Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells. Can J Physiol Pharmacol2001; 79:876-884
98. Bauer B, Hartz AM, Miller DS. Tumor necrosis factor alpha and endothelin-I increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol2007; 71 :667-675
99. Zhong Y, Hennig B, Toborek M. Intact lipid rafts regulate HIV-I Tat protein-induced activation of the Rho signaling and upregulation ofP-glycoprotein in brain endothelial cells. J Cereb Blood Flow Metab 2010; 30:522-533
100. Pan W, Yu C, Hsuchou H, et al. The role of cerebral vascular NFkappaB in LPS-induced inflammation: Differential regulation of efflux transporter and transporting cytokine receptors. Cell Physiol Biochem 2010; 25:623-630
101. Ott M, Fricker G, Bauer B. Pregnane X receptor (PXR) regulates P-glycoprotein at the blood-brain barrier: Functional similarities between pig and human PXR. J Pharmacol Exp Ther 2009; 329: 141-149
102. Wang X, Sykes DB, Miller DS. Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. Mol Pharmacol 2010; 78:376-383
103. Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci 2010; 31 :246-254
104. Kis 0, Robillard K, Chan GN, et al. The complexities of antiretroviral drug-drug interactions: Role of ABC and SLC transporters. Trends Pharmacol Sci 2010; 31 :22-35
105. Keppler D. Multidrug resistance proteins (MRPs, ABCCs): Importance for pathophysiology and drug therapy. Handb Exp Pharmacol 20 II; 299-323
106. Borst P, Evers R, Kool M, et al. A family of drug transporters: The multidrug resistance-Associated proteins. J Natl Cancer Tnst 2000; 92: 1295-1302
107. Bakos E, Evers R, Szakacs G, et al. Functional multi drug resistance protein (MRP I) lacking the N-Terminal transmembrane domain. JBiol Chern 1998; 273:32167-32175
108. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-1654
109. Leier T, Jedlitsehky G, Buchholz U, et al. A TP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Bioehem J 1996; 314:433-437
110. Hipfner DR, Deeley RG, Cole SP. Structural, mechanistic and clinical aspects ofMRP I. Bioehim Biophys Acta 1999; 1461:359-376
111. Leslie EM, Deeley RG, Cole SP. Toxicological relevance of the multi drug resistance protein I, MRP I (ABCCl) and related transporters. Toxicology 2001; 167:3-23
112. Rappa G, Lorieo A, Flavell RA, et al. Evidence that the multidrug resistance protein (MRP) functions as a co-Transporter of glutathione and natural product toxins. Cancer Res 1997; 57:5232-5237
113. Loe DW, Deeley RG, Cole SP. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): Evidence for eotransport with reduced glutathione. Cancer Res 1998; 58:5130-5136
114. Gazzin S, Berengeno AL, Strazielle N, et al. Modulation ofMrpl (ABCc1) andPgp (ABCbl) by bilirubin at the blood-CSF and blood-brain barriers in the Gunn rat. PLoS One 20 II; 6:e 16165
115. Decleves X, Fajae A, Lehmann-Che J, et al. Molecular and functional MDRI-Pgp and MRPs expression in human glioblastoma multi forme cell lines. Tnt J Cancer 2002; 98: 173-180
116. Wang F, Zhou F, Kruh GD, et al. Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. Neuro Oneol 2010; 12: I 043-1 049
117. Hayashi K, Pu H, Andras IE, et al. HIV-TAT protein upregulates expression of multidrug resistance protein I in the blood-brain barrier. J Cereb Blood Flow Metab 2006; 26: I 052-1 065
118. Ronaldson PT, Ashraf T, Bendayan R. Regulation of multi drug resistance protein 1 by tumor necrosis factor alpha in cultured glial cells: Involvement of nuclear faetor-kappaB and e-Jun N-Terminal kinase signaling pathways. Mol Pharmaeol201 0; 77:644-659
119. Kruh GD, Belinsky MG, Gallo JM, et al. Physiological and pharmacological functions ofMrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice. Cancer Metastasis Rev 2007; 26:5-14
120. Hirrlinger J, Konig J, Keppler D, et al. The multidrug resistance protein MRPI mediates the release of glutathione disulfide from rat astroeytes during oxidative stress. J Neuroehem 2001; 76:627-636
121. Lai L, Tan TM. Role of glutathione in the multidrug resistance protein 4 (MRP4/ ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Bioehem J 2002; 361 :497-503
122. Wijnholds J, Mol CA, van DL, et al. Multidrug-resistanee protein 5 is a multispeeifie organic anion transporter able to transport nueleotide analogs. Proe Natl Aead Sci USA 2000; 20(97):7476-7481
123. Minich T, Riemer J, Schulz ill, et al. The multidrug resistance protein I (Mrpl), but not Mrp5, mediates export of glutathione and glutathione disulfide from brain astroeytes. J Neuroehem 2006; 97:373-384
124. Keppler D, Konig J, Buchler M. The canalicular multidrug resistance protein, eMRPIMRP2, a novel conjugate export pump expressed in the apical membrane ofhepatoeytes. Adv Enzyme Regu11997; 37: 321-333
125. Choudhuri S, Cherrington NJ, Li N, et al. Constitutive expression of various xenobiotie and endobiotic transporter mRNAs in the choroid plexus ofrats. Drug Metab Dispos 2003; 31: 1337-1345
126. Potsehka H, Fedrowitz M, Loseher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts anti epileptic drug activity. J Pharmaeol Exp Ther 2003; 306: 124-131
127. Zeleer N, Saeki T, Reid G, et al. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J BioI Chern 2001; 276:46400-46407
128. Zhang Y, Han H, Elmquist WF, et al. Expression of various multidrugresistanee-Assoeiated protein (MRP homologues in brain mierovessel endothelial cells. Brain Res 2000; 876: 148-153
129. Soontornmalai A, Vlaming ML, Fritsehy JM. Differential, strain-specific cellular and subcellular distribution of multi drug transporters in murine choroid plexus and blood-brain barrier. Neuroscience 2006; 138: 159-169
130. Nics AT, Jedlitsehky G, Konig J, et al. Expression and immunoloealization of the multidrug resistance proteins, MRPI-MRP6 (ABCCI-ABCC6), in human brain. Neuroscience 2004; 129:349-360
131. Calatozzolo C, Gelati M, Ciusani E, et al. Expression of drug resistance proteins Pgp, MRPl, MRP3, MRP5 and GST-pi in human glioma. JNeurooneol2005; 74:113-121
132. Chen ZS, Lee K, Kruh GD. Transport of cyclic nueleotides and estradiol 17-beta-D-glueuronide by multi drug resistance protein 4. Resistance to 6-mereaptopurine and 6-Thioguanine. J Bioi Chern 2001; 276:33747-33754
133. Zhang Y, Schuetz JD, Elmqu ist WF, et al. Plasma membrane local ization of mu Itidrug resistance-Associated protein homologs in brain capillary endothelial cells. J Pharmaeol Exp Ther 2004; 311 :449-455
134. Roberts LM, Black DS, Raman C, et al. Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier by in vivo biotinylation. Neuroscience 2008; 155:423-438
135. Leggas M, Adachi M, Scheffer GL, et al. Mrp4 confers resistance to topoteean and protects the brain from chemotherapy. Mol Cell BioI 2004; 24:7612-7621
136. Ballerini P, Di TP, Ciccarelli R, et al. Glial cells express multiple A TP binding cassette proteins which are involved in ATP release. Neuroreport 2002; 13: 1789-1792
137. Ronaldson PT, Bendayan R. HIV-I viral envelope glycoprotein gpl20 produces oxidative stress and regulates the functional expression of multi drug resistance protein-I (Mrpl) in glial cells. J Neurochem 2008; 106: 1298-1313
138. Belinsky MG, Guo P, Lee K, et al. Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage. Cancer Res 2007; 67:262-268
139. Zhang Y, Schuetz JD, Elmquist WF, et al. Plasma membrane localization of multidrug resistance-Associated protein homo logs in brain capillary endothelial cells. J Pharmacol Exp Ther 2004; 311 :449-455
140. Zhang Y, Han H, Elmquist WF, et al. Expression of various multi drug resistance-Associated protein (MRP homologues in brain microvessel endothelial cells. Brain Res 2000; 876:148-153
141. Kubota H, Ishihara H, Langmann T, et al. Distribution and functional activity of P-glycoprotein and multidrug resistance-Associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res 2006; 68:213-228
142. Varadi A, Szabo Z, Pomozi V, et al. ABCC6 as a target in Pseudoxanthoma Elasticum. Curr Drug Targets 2011; 12:671-682
143. Takayanagi S, Kataoka T, Ohara 0, et al. Human A TP-binding cassette transporter ABCC I 0: Expression profile and p53-dependent upregulation. J Exp Ther Onco12004; 4:239-246
144. Kao HH, Huang JD, Chang MS. cDNA cloning and genomic organization of the murine MRP7, a new ATP-binding cassette transporter. Gene 2002; 20(286):299-306
145. Oguri T, Bessho Y, Achiwa H, et al. MRP8/ABCCII directly confers resistance to 5-fluorouracil. Mol Cancer Ther 2007; 6: 122-127
146. Bera TK, Lee S, Salvatore G, et al. MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol Med 2001; 7:509-516
147. Bortfeld M, Rius M, Konig J, et al. Human multi drug resistance protein 8 (MRP81 ABCC II), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. Neuroscience 2006; 137:1247-1257
148. Bera TK, Iavarone C, Kumar V, et al. MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proc Natl Acad Sci USA 2002; 99:6997-7002
149. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95:15665-15670
150. Mao Q, Unadkat JD. Role ofthe breast cancerresistance protein (ABCG2) in drug transport. AAPS J 2005; 7:EI18-E133
151. Merino G, Alvarez AI, Pulido MM, et al. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics, and affects their oral availability, pharmacokinetics and milk secretion. Drug Metab Dispos 2006; 34:690-695
152. Hori S, Ohtsuki S, Tachikawa M, et al. Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s). J Neurochem 2004; 90:526-536
153. Zhang W, Mojsilovic-Petrovic J, Andrade MF, et al. The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J 2003; 17:2085-2087
154. Lee G, Babakhanian K, Ramaswamy M, et al. Expression ofthe A TP-binding cassette membrane transporter, ABCG2, in human and rodent brain microvessel endothelial and glial cell culture systems. Pharm Res 2007; 24: 1262-1274
155. Eisenblatter T, Galla HJ. A new multidrug resistance protein at the blood-brain barrier. Biochem Biophys Res Commun 2002; 293: 1273-1278
156. Eisenblatter T, Huwel S, Galla HJ. Characterisation of the brain multidrug resistance protein (BMDPI ABCG2/BCRP) expressed at the blood-brain barrier. Brain Res 2003; 971:221-231
157. Hartz AM, Mahringer A, Miller DS, et al. 17-beta-Estradiol: A powerful modulator of blood-brain barrier BCRP activity. J Cereb Blood Flow Metab 2010; 30:1742-1755
158. Cistemino S, Mercier C, Bourasset F, et al. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 2004; 64:3296-3301
159. Breedveld P, Pluim D, Cipriani G, et al. The effect ofBcrpl (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration ofimatinib in patients. Cancer Res 2005; 65:2577-2582
160. Gardner ER, Smith NF, Figg WD, et al. Influence of the dual ABCB I and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice. J Exp Clin Cancer Res 2009; 28(99):99
161. Agarwal S, Sane R, Ohlfest JR, et al. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther 20 II; 336:223-233
162. Hartz AM, Madole EK, Miller DS, et al. Estrogen receptor beta signaling through phosphatase and tensin homolog/phosphoinositide 3-kinasel Akt/glycogen synthase kinase 3 down-regulates blood-brain barrier breast cancer resistance protein. J Pharmacol Exp Ther 2010; 334:467-476
163. Hirai T, Fukui Y, Motojima K. PPAR alpha agonists positively and negatively regulate the expression of several nutrient/drug transporters in mouse small intestine. Bioi Pharm Bull 2007; 30:2185-2190
164. Szatmari I, Vamosi G, Brazda P, et al. Peroxisome proliferator-Activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. J BioI Chern 2006; 281:23812-23823
165. Von Wedel-Parlow M, Wolte P, Galla HJ. Regulation of major efflux transporters under inflammatory conditions at the blood-brain barrier in vitro. J Neurochem 2009; III: 111-118
166. He L, Vasiliou K, Nebert DW. Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics 2009; 3:195-206
167. Hagenbuch B, Meier PJ. Organic anion transportingpolypeptidesoftheOA TP/SLC21 family: Phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 2004; 447:653-665
168. Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: Function and regulation. Pharmacol Rev 2010; 62:1-96
169. Konig J. Uptake transporters of the human OATP family: Molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorph isms. Handb Exp Pharmacol 2011; 201:1-28
170. Burckhardt G, Burckhardt BC. In vitro and in vivo evidence ofthe importance of organic anion transporters (OATs) in drug therapy. Handb Exp Pharmacol2011; 29-104
171. Rizwan AN, BurckhardtG. Organic anion transportersofthe SLC22 family: Biopharmaceutical, physiological and pathological roles. Pharm Res 2007; 24:450-470
172. Satlin LM, Amin V, Wolkoff A W. Organic anion transporting polypeptide mediates organic anion/HC03-exchange. J BioI Chern 1997; 272:26340-26345
173. Leuthold S, Hagenbuch B, Mohebbi N, et al. Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am J Physiol Cell Physiol2009; 296:C570-C582
174. Li L, Lee TK, Meier PJ, et al. Identification of glutathione as a driving force and leukotriene C4 as a substrate for oatp I, the hepatic sinusoidal organic solute transporter. J BioI Chern 1998; 273: 16184-16191
175. Li L, Meier PJ, Ballatori N. Oatp2 mediates bidirectional organic solute transport: A role for intracellular glutathione. Mol Pharmacol2000; 58:335-340
176. Shi X, Bai S, Ford AC, et al. Stable inducible expression of a functional rat liver organic anion transport protein in HeLa cells. J BioI Chern 1995; 270:25591-25595
177. Kis 0, Zastre JA, Ramaswamy M, et al. pH dependence of organic anion-Transporting polypeptide 2B I in Caco-2 cells: Potential role in antiretroviral drug oral bioavailability and drug-drug interactions. J Pharmacol Exp Ther 2010; 334:1009-1022
178. Grube M, Kock K, Kamer S, et al. Modification of OA TP2B I-mediated transport by steroid hormones. Mol Pharmacol 2006; 70: 1735-1741
179. Eckhardt U, Schroeder A, Stieger B, et al. Polyspecific substrate uptake by the hepatic organic anion transporter Oatp I in stably transfected CHO cells. Am J Physiol 1999; 276:G I 037-G I 042
180. Shimizu M, Fuse K, Okudaira K, et al. Contribution ofOATP (organic anion-Transporting polypeptide ) family transporters to the hepatic uptake offexofenadine in humans. Drug Metab Dispos 2005; 33:1477-1481
181. Ose A, Kusuhara H, Endo C, et al. Functional characterization of mouse organic anion transporting peptide la4 in the uptake and efflux of drugs across the blood-brain barrier. Drug Metab Dispos 2010; 38: 168-176
182. Nakai D, Nakagomi R, Furuta Y, et al. Human liver-specific organic anion transporter, LST-I, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 2001; 297:861-867
183. Reichcl C, Gao B, Van MJ, et al. Localization and function of the organic anion-Transporting polypeptide Oatp2 in rat liver. Gastroenterology 1999; 117:688-695
184. Nozawa T, Tarnai I, Sai Y, et al. Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination ofthe opioid pentapeptide analogue [D-Ala2, D-Leu5J-enkephalin. JPharm PharmacoI2003; 55: 10 13-1020
185. Gao B, Hagenbuch B, Kullak-Ublick GA, et al. Organic anion-Transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Tber 2000; 294:73-79
186. Van De Steeg E, van EA, Wagenaar E, et al. High impact ofOatpI al1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin Cancer Res 20 II; 17:294-301
187. Hartkoom RC, Kwan WS, Shallcross V, et al. HIV protease inhibitors are substrates for OATPIA2, OATPIB I andOATPIB3 and lopinavir plasma concentrations
188. Su Y, Zhang X, Sinko PJ. Human organic anion-Transporting polypeptide OATP-A (SLC2IA3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm 2004; 1:49-56
189. Vavricka SR, Van MJ, Ha HR, et al. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002; 36: 164-172
190. Cheng X, Maher J, Chen C, et al. Tissue distribution and ontogeny of mouse organic anion transporting polypcptidcs (Oatps). Drug Mctab Dispos 2005; 33:1062-1073
191. Ohtsuki S, Takizawa T, Takanaga H, et al. Localization of organic anion transporting polypeptide 3 (oatp3 in mousc brain parcnchymal and capillary cndothelial cclls. J Ncurochcm 2004; 90:743-749
192. Hagenbuch B and Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 2003;1609:1-18
193. Angeletti RH, Novikoff PM, Juvvadi SR, et al. The choroid plexus epithelium is the site of the organic anion transport protcin in thc brain. Proc Natl Acad Sci USA 1997; 94:283-286
194. Gao B, Stieger B, Noe B, et al. Localization oftheorganic anion transporting polypeptide 2 (Oatp2) in capillary cndothclium and choroid plexus cpithclium of rat brain. J Histochcm Cytochcm 1999; 47: 1255-1264
195. Huber RD, Gao B, Sidler Pfandler MA, et al. Characterization oftwo splice variants of human organic anion transportingpolypcptidc 3Al isolatcdfromhuman brain. AmJ Physiol CcllPhysiol2007; 292:C795-C806
196. Tohyama K, Kusuhara H, Sugiyama Y. Involvement of multi specific organic anion transporter, Oatp 14 (Slc21aI4), in thc transport ofthyroxinc across thc blood-brain barricr. Endocrinology2004; 145:4384-4391
197. Pizzagalli F, Hagenbuch B, Stieger B, et al. Identification of a novel human organic anion transporting polypcptidc as a high affinity thyroxinc transportcr. Mol Endocrinol2002; 16:2283-2296
198. Bronger H, Konig J, Kopplow K, et al. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and thc blood-Tumor barricr. Canccr Rcs 2005; 65: 11419-11428
199. Dagenais C, Ducharme J, Pollack GM. Uptake and efflux of the peptidic delta-opioid receptor agonist. Ncurosci Lctt 2001; 301:155-158
200. Sugiyama D, Kusuhara H, Shitara Y, et al. Characterization of the efflux transport of 17 bcta-cstradiol-D-17bcta-glucuronidc from thc brain across thc blood-brain barricr. J Pharmacol Exp Ther 2001; 298:316-322
201. Kusuhara H, Sugiyama Y. Activc cfflux across thc blood-brain barricr: Role ofthc solutc carricr family. NeuroRx 2005; 2:73-85
202. Cvctkovic M, Lcakc B, Fromm MF et al. OATP and P-glycoprotcin transportcrs mcdiatc thc ccllular uptake and excretion of fexofenadine. Drug Metab Dispos 1999; 27:866-871
203. Sckinc T, Watanabc N, Hosoyamada M et al. Exprcssion cloning and charactcrization of a novel multispccific organic anion transporter. J BioI Chern 1997; 272: 18526-18529
204. Van Wcrt AL, Gionfriddo MR, Swcct DH. Organic anion transportcrs: Discovcry, pharmacology, rcgulation and roles in pathophysiology. Biopharrn Drug Dispos 2010; 31: 1-71
205. Ohtsuki S, Kikkawa T, Mori S et al. Mousc rcduccd in ostcoselcrosis transportcr functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Thcr 2004; 309:1273-1281
206. Sweet DH, Miller DS, Pritchard JB, et al. Impaired organic anion transport in kidney and choroid plexus of organic anion transportcr 3 (Oat3 (Slc22a8)) knockout micc. J BioI Chcm 2002; 277:26934-26943
207. Bahn A, Ljubojevic M, Lorenz H, et al. Murine renal organic anion transporters mOAT I and mOA T3 facilitate thc transport ofncuroactivc tryptophan mctabolitcs. Am J Physiol Cell Physiol2005; 289:CI075-CI084
208. Enomoto A, Wempe MF, Tsuchida H, et al. Molecular identification of a novel camitine transporter specific to human tcstis.Insights into thcmcchanism of camitincrccognition. J BioI Chcm2002; 277:36262-36271
209. Strazielle N, Khuth ST, Murat A, et al. Pro-inflammatory cytokines modulate matrix m, et alloproteinase sccrction and organic anion transport at thc blood-ccrcbrospinal fluid barricr. J Ncuropathol Exp Ncurol 2003; 62: 1254-1264
210. Kocpscll H, Lips K, Volk C. Polyspccific organic cation transportcrs: Structurc, function, physiological roles, and biopharmaceutical implications. Pharrn Res 2007; 24:1227-1251
211. Vialou V, Amphoux A, Zwart R et al. Organic cation transportcr 3 (Slc22a3) is implicatcd in salt-intakc regulation. J Neurosci 2004; 24:2846-2851
212. Kitaichi Y, Inouc T, Nakagawa S et al. Effcct ofmilnacipran on cxtraccllular monoaminc conccntrations in the medial prefrontal cortex ofrats pre-Treated with lithium. Eur J Pharmacol 2005; 516:219-226
213. Aoyama N, Takahashi N, Kitaichi K et al. Association bctwccn gcnc polymorphisms of SLC22A3 and methamphetamine use disorder. Alcohol Clin Exp Res 2006; 30: 1644-1649
214. Tarnai I, Ohashi R, Nczu J et al. Molccular and functional idcntification of sodium ion-dcpcndcnt, high affinity human camitine transporter OCTN2. J BioI Chern 1998; 273:20378-20382
215. Tarnai I, Ohashi R, Nczu Jl et al. Molecular and functional charactcrization of organic cation/camitinc transporter family in mice. J BioI Chern 2000; 275:40064-40072
216. Miccz D, Januszcwicz E, Czcrcdys M et al. Localization of organic cation/camitinc transportcr (OCTN2 in cells forming the blood-brain barrier. J Neurochem 2008; 104: 113-123
217. Inazu M, Takcda H, Machara K et al. Functional cxprcssion ofthc organic cation/camitinc transportcr 2 in rat astrocytes. J Neurochem 2006; 97:424-434
218. Moriyama Y, Hiasa M, Matsumoto T, et al. Multidrug and toxic compound extrusion (MA TE)-Type proteins as anchor transporters for the excretion of metabolic waste products and xenobiotics. Xenobiotica 2008; 38:1107-1118
219. Hiasa M, Matsumoto T, Komatsu T, et al. Functional characterization of testis-specific rodent multidrug and toxic compound extrusion 2, a class III MATE-Type polyspecific H+/organic cation exporter. Am J Physiol Cell Physiol2007; 293:CI437-CI444
220. Redzic ZB, Biringer J, Barnes K, et al. Polarized distribution of nucleoside transporters in rat brain endothclial and choroid plexus epithelial cells. J Neurochem 2005; 94: 1420-1426
221. King AE, Ackley MA, Cass CE, et al. Nucleoside transporters: From scavengers to novel therapeutic targets. Trends Pharmacol Sci 2006; 27 :416-425
222. Pastor-Anglada M, Cano-Soldado P, Errasti-Murugarren E, et al. SLC28 genes and concentrative nucleoside transporter (CNT) proteins. Xenobiotica 2008; 38:972-994
223. Ritzel MW, Yao SY, Huang MY, et al. Molecular cloning and functional expression ofcDNAs encoding a human Na+-nucleoside cotransporter (hCNTl). Am J Physiol1997; 272:C707-C714
224. Shin HC, Landowski CP, Sun D, et al. Functional expression and characterization ofa sodium-dependent nucleoside transporter hCNT2 cloned from human duodenum. Biochem Biophys Res Commun 2003; 307:696-703
225. Lu H, Chen C, Klaassen C. Tissue distribution of concentrative and equilibrative nucleoside transporters in male and female rats and mice. Drug Metab Dispos 2004; 32: 1455-1461
226. Young JD, Yao SY, Sun L, et al. Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica 2008; 38:995-1021
227. Hyde RJ, Cass CE, Young JD, et al. The ENT family of eukaryote nucleoside and nucleobase transporters: Recent advances in the investigation of structure/function relationships and the identification of novel isoforms. Mol Membr BioI 2001; 18:53-63.
228. Redzic ZB, Malatiali SA, Grujicic D, et al. Expression and functional activity of nucleoside transporters in human choroid plexus. Cerebrospinal Fluid Res 2010; 7:2
229. Yao SY, Ng AM, Sundaram M, et al. Transport of antiviral 3'-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol Membr BioI 2001 ; 18:161-167
230. Strazielle N, BelinMF, Ghersi-Egea JF. Choroid plexus controls brain availability of anti-HI V nucleoside analogs via pharmacologically inhibitable organic anion transporters. AIDS 2003; 17: 1473-1485
231. GibbsJE, JayabalanP, Thomas SA. Mechanisms by which 2' ,3'-dideoxyinosine (ddI) crosses the guinea-pig CNS barriers; relevance to HTV therapy. J Neurochem 2003; 84:725-734
232. Baldwin SA, Yao SY, Hyde RJ, et al. Functional characterization ofnovcl human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J BioI Chern 2005; 280: 15880-15887
233. Brandsch M. Transport of drugs by proton-coupled peptide transporters: Pearls and pitfalls. Expert Opin Drug Metab Toxicol2009; 5:887-905
234. Terada T, Saito H, Sawada K, et al. N-Terminal halves of rat H+/peptide transporters are responsible for their substrate recognition. Pharm Res 2000; 17: 15-20
235. Rubio-Aliaga T, Daniel H. Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica 2008; 38: I 022-1042
236. Biegel A, Gebauer S, Brandsch M, et al. Structural requirements for the substrates of the H+/peptide cotransporter PEPT2 determined by three-dimensional quantitative structure-Activity rclationship analysis. J Med Chern 2006; 49:4286-4296
237. Berger UV, Hediger MA. Distribution of peptide transporter PEPT2 mRNA in the rat nervous system. Anat Embryol (Berl) 1999; 199:439-449
238. Shu C, ShenH, Teuscher NS, et al. Role ofPEPT2 in peptide/mimetic trafficking at the blood-cerebrospinal fluid barrier: Studies in rat choroid plexus epithelial cells in primary culture. J Pharmacol Exp Ther 2002; 30 I :820-829
239. Smith DE, Hu Y, Shen H, et al. Distribution of glycylsarcosine and cefadroxil among cerebrospinal fluid, choroid plexus, and brain parenchyma after intracerebroventricular injection is markedly different between wild-Type and Pept2 null mice. J Cereb Blood Flow Metab 20 II; 31 :250-261
240. Xiang J, Hu Y, Smith DE, et al. PEPT2-mediated transport of 5-Aminolevulinic acid and carnosine in astrocytes. Brain Res 2006; 1122: 18-23
241. Popovic M, Sarngadharan MG, Read E, et al. Detection, isolation, and continuous production of cytopathic retroviruses (HTL V-III) from patients with AIDS and pre-AIDS. Science 1984; 224:497-500
242. Kedzierska K, Crowe SM. The role ofmonocytes andmacrophages in the pathogenesis of HI V-I infection. Curr Med Chern 2002; 9: 1893-1903
243. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-Iymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 20(220):868-871
244. Kramer-Hammerle S, Rothenaigner I, WolffH, et al. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res 2005; III: 194-213
245. Albright AV, Soldan SS, Gonzalez-Scarano F. Pathogenesis of human immunodeficiency virus-induced neurological disease. J NeuroviroI2003; 9:222-227
246. Vivithanapom P, Heo G, Gamble J, et al. Neurologic disease burden in treated HIV / AIDS predicts survival: A population-based study. Neurology 2010; 75:1150-1158
247. Langford D, Grigorian A, Hurford R, et al. Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J Neuropathol Exp Neurol 2004; 63: 1038-1047
248. Hayashi K, Pu H, Tian J, et al. HIV-Tat protein induces P-glycoprotein expression in brain microvascular endothelial cells. J Neurochem 2005; 93:1231-1241
249. Poller B, Drewe J, Krahenbuhl S, et al. Regulation of BCRP (ABCG2) and P-glycoprotein (ABCBI) by cytokines in a model of the human blood-brain barrier. Cell Mol Neurobiol201O; 30:63-70
250. Ashraf T, Ronaldson PT, Persidsky Y, et al. Regulation ofP-glycoprotein by human immunodeficiency virus-I in primary cultures of human f, et al astrocytes. J Neuosci Res 2011; In press
251. Chandler B, Almond L, FordJ, et al. The effects of protease inhibitors andnonnueleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr 2003; 33:551-556
252. Chan GN, Tozammel HM, Cummins CL, et al. Regulation ofP-glycoprotein by Orphan Nuclear Receptors in Human Brain Microvessel Endothelial Cells. J Neurochem 20 II; 10-4159
253. Zastre JA, Chan GN, Ronaldson PT, et al. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J Neurosci Res 2009; 87: I 023-1 036
254. Bousquet L, Roucairol C, Hembury A, et al. Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier. AIDS Res Hum Retroviruses 2008; 24:1147-1154
255. Zembruski NC, Buchel G, Jodicke L, et al. Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J Antimicrob Chemother 20 II; 66:802-812
256. Giulian D. Microglia and the immune pathology of Alzheimer disease. Am J Hum Genet 1999; 65: 13-18
257. Vogelgesang S, Warzok RW, Cascorbi I, et al. The role ofP-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2004; I: 121-125
258. Lam FC, Liu R, Lu P, et al. Beta-Amyloid efflux mediated byp-glycoprotein. JNeurochem2001; 76: 1121-1128
259. Knhnke D, Jedlitschky G. Grube MetaI.MDRI-P-Glycoprotein(ABCBI)Mediates Transport of Alzheimer's amyloid-beta peptides-implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Patho12007; 17:347-353
260. Hartz AM, Miller DS, Bauer B. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol Pharrnacol2010; 77:715-723
261. Tai LM, Loughlin AJ, Male DK, et al. P-glycoprotein and breast cancer resistance protein restrict apical-To-basolateral permeability of human brain endothelium to amyloid-beta. J Cereb Blood Flow Metab 2009; 29: I 079-1 083
262. Cirrito JR, Deane R, Fagan AM, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 2005; 115:3285-3290
263. Ito S, Ohtsuki S, Terasaki T. Functional characterization of the brain-To-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. Neurosci Res 2006; 56:246-252
264. Silverberg GD, Messier AA, Miller MC, et al. Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J Neuropathol Exp Neurol 2010; 69: I 034-1 043
265. Xiong H, Callaghan D, Jones A, et al. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta (1-40) peptides. J Neurosci 2009; 29:5463-5475
266. Shen S, Callaghan D, Juzwik C, et al. ABCG2 reduces ROS-mediated toxicity and inflammation: A potential role in Alzheimer's disease. J Neurochem 2010; 114: 1590-1604
267. Sultana R, Butterfield DA. Oxidatively modified GSTand MRP I in Alzheimer's disease brain: Implications for accumulation of reactive lipid peroxidation products. Neurochem Res 2004; 29:2215-2220
268. Bartels AL, Leenders KL. Parkinson's disease: The syndrome, the pathogenesis and pathophysiology. Cortex 2009; 45:915-921
269. Westerlund M, Hoffer B, Olson L. Parkinson's disease: Exit toxins, enter genetics. Prog Neurobiol201 0; 90:146-156
270. Koller W, Vetere-Overfield B, Gray C, et al. Environmental risk factors in Parkinson's disease. Neurology 1990; 40:1218-1221
271. Westerlund M, Belin AC, Anvret A, et al. Association of a polymorphism in the ABCBI gene with Parkinson's disease. Parkinsonism Relat Disord 2009; 15:422-424
272. Lee CG, TangK, Cheung YB, et al. MDRI, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. J Med Genet 2004; 41 :e60
273. Westerlund M, Belin AC, Olson L, et al. Expression of multi-drug resistance I mRNA in human and rodent tissues: Reduced levels in Parkinson patients. Cell Tissue Res 2008; 334: 179-185
274. Kortekaas R, Leenders KL, van Oostrom J C, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neuro12005; 57:176-179
275. Bartels AL, Willemsen AT, Kortekaas R, et al. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm 2008; 115: I 001-1 009
276. Soares-Da-Silva P, Serrao MP. Outward transfer of dopamine precursor L-3,4-dihydroxyphenylalanine (L-dopa) by native and human P-glyeoprotein in LLC-PK(I) andLLC-GA5 eo1300renal cells. JPhannaeol Exp Ther 2000; 293:697-704
277. Vautier S, Milane A, Fernandez C, et al. Interactions between antiparkinsonian drugs and ABCBIl-glyeoproteinatthe blood-brain barrier in a rat brain endothelial cell model. NeurosciLett 2008 442 19-23
278. Shiraki N, Okamura K, Tokunaga J, et al. Bromoeriptine reverses P-glyeoprotein-mediated multidrug resistance in tumor cells. Jpn J Cancer Res 2002; 93:209-215
279. Vautier S, Laeomblez L, Chaeun H, et al. Interactions between the dopamine agonist, bromoeriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse. Eur J Pharm Sci 2006; 27: 167-174
280. Uhr M, Ebinger M, Rosenhagen MC, et al. The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice. Neurosei Lett 2005; 383:73-76
281. Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 1999; 34: 109-122
282. Volk H, Potsehka H, Loseher W. Immunohistochemical localization ofP-glyeoprotein in rat brain and detection of its increased expression by seizures arc sensitive to fixation and staining variables. J Histochem Cytoehem 2005; 53:517-531
283. Potsehka H, Loscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 2001; 42: 1231-1240
284. Tishler DM, Weinberg KI, Hinton DR, et al. MDRI gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995; 36: 1-6
285. VolkHA, Burkhardt K, Potsehka H, et al. Neuronal expression ofthe drug efflux transporter P-glyeoprotein in the rat hippocampus after limbic seizures. Neuroscience 2004; 123:751-759
286. Van Vliet EA, Redeker S, Aroniea E, et al. Expression of multidrug transporters MRPI, MRP2, and BCRP shortly after status epileptieus, during the latent period, and in chronic epileptic rats. Epilepsia 2005; 46:1569-1580
287. Sisodiya SM, Lin WR, Squier MV, et al. Multidrug-resistanee protein I in focal cortical dysplasia. Lancet 2001; 357:42-43
288. Sisodiya SM, Lin WR, Harding BN, et al. Drug resistance in epilepsy: Expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002; 125:22-31
289. Kim WJ, Lee JH, Yi J, et al. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmaeogenet Genomies 2010; 20:249-256
290. Luna-Tortos C, Fedrowitz M, Loscher W. Several major antiepileptic drugs arc substrates for human P-glycoprotein. Neuropharmacology 2008; 55: 1364-1375
291. Sills GJ, Kwan P, Butler E, et al. P-glyeoprotein-mediated efflux of antiepileptie drugs: Preliminary studies in mdrla knockout mice. Epilepsy Behav 2002; 3:427-432
292. Schinkel AH, Wagenaar E, Mol CA, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97:2517-2524
293. Luna-Tortos C, Fedrowitz M, Loscher W. Evaluation oftransport of common antiepileptic drugs by human multi drug resistance-Associated proteins (MRPI, 2 and 5) that are overexpressed in pharmaeoresistant epilepsy. Neurophannaeology 2010; 58:1019-1032
294. Ambroziak K, Kuteykin-Teplyakov K, Luna-Tortos C, et al. Exposure to antiepileptie drugs does not alter the functionality of P-glyeoprotein in brain capillary endothelial and kidney cell lines. Eur J Pharmacol 2010; 628:57-66
295. Dc Vries NA, Buckle T, Zhao J, et al. Restricted brain penetration ofthe tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs, 2010; Epub
296. Agarwal S, Sane R, Gallardo JL, et al. Distribution of gefitinib to the brain is limited by P-glyeoprotein (ABCB I) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmaeol Exp Ther 2010; 334:147-155
297. Regina A, Demeule M, Laplante A, et al. Multidrug resistance in brain tumors: Roles of the blood-brain barrier. Cancer Metastasis Rev 2001; 20:13-25
298. Spiegl-Kreinecker S, Buehroithner J, ElblingL, et al. Expression and functional activity ofthe ABC-Transporter proteins P-glyeoprotein and multi drug-resistance protein I in human brain tumor cells and astroeytes. J Neurooneol2002; 57:27-36
299. Haber M, Smith J, Bordow SB et al. Association of high-level MRP I expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oneo12006; 24: 1546-1553
300. Burkhart CA, Watt F, Murray J et al. Small-molecule multidrug resistance-Associated protein I inhibitor revers an increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res 2009; 69:6573-6580
301. Chen L, Feng P, Li S, et al. Effect of hypoxia-inducible faetor-I alpha silencing on the sensitivity of human brain glioma cells to doxorubiein and etoposide. Neuroehem Res 2009; 34:984-990
302. Zhang Y, Laterra J, Pomper MG. Hedgehog pathway inhibitor HhAntag69I is a potent inhibitor of ABCG21 BCRP and ABCBI/Pgp. Neoplasia 2009; 11:96-101
303. Kuan CT, Wakiya K, Herndon JE, et al. MRP3: A molecular target for human glioblastoma multiforme immunotherapy. BMC Cancer 2010; 10(468):468